Business Roundtable
The Insiders' Take on Outsourcing - Building Value Without Owning the Infrastructure
Thursday, October 30, 2008
5:00pm - 6:15pm
Telegraph Hill
Sophisticated investors and senior executives alike are increasingly asking how the services of contract organizations can be leveraged to aggressively manage resources through preclinical, clinical and manufacturing stages of development. Focusing on corporate and financial strategy and the investor’s perspective, this panel will review case studies as well as the analytical arguments – pro and con - for outsourcing. Gain an insider’s perspective on how and when to make critical outsourcing decisions for emerging private and public companies. Whether you are a CEO, venture investor with a board seat or weighing how your investment in a public biotech may fare in a company with limited resources and a growing burn rate -- when to outsource and who to select is one of the most fundamental decisions a company can make today. This panel will focus on how to achieve and even exceed objectives when you decide to entrust your results to contractors while avoiding formidable internal investment and expense.
Moderator
- William Greene, MD, General Partner, MPM Capital, LP
Panelists
- Jamila Joseph, General Manager, Reliance Clinical Research Services
- Krishna Kanumuri, Chief Operating Officer, Sai Advantium
- Dinesh V. Patel, Founder and Owner, IND AlChemist Inc.
- Robert Booth, Partner, TPG Growth; Founder and Executive Chairman of Virobay
Who's Who
William Greene, MD Dr. Greene joined MPM Capital in 2002 from Genentech, where from 1998-2002 he was a Senior Clinical Scientist and Epidemiologist, with clinical development, regulatory and drug safety responsibilities spanning several therapeutic areas. Prior to Genentech, Dr. Greene was at Yale where he trained in Internal Medicine and Radiology, taught medicine and did clinical research. Dr. Greene has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology), a Howard Hughes Medical Institute Research Scholar at the NIH (molecular neurobiology), taught medicine, and managed a private medical practice. He has been awarded the Henry Christian Award for outstanding research from the American Federation of Clinical Research and is a member of the American College of Physicians and the Society for Clinical Epidemiology and Health Care Research. He received a B.A. degree (Phi Beta Kappa) from Wesleyan University and an M.D. degree from UCSF, where he is currently an Assistant Professor of Medicine. Dr. Greene currently serves on the Boards of Alsius, Archus Orthopedics, EsophyX, QuatRx Pharmaceuticals, and Synergia Pharmaceuticals.
Jamila Joseph Ms. Jamila Joseph is General Manager at Reliance Clinical Research Services, India. She is a biochemist by training and taught Biochemistry at the University of Mumbai before she joined Quintiles, Inc. in February 1998. At Quintiles, she held various posts ranging from site monitor and Clinical Team Leader to Data Coder, Lead Data Manager, Medical Writer, Training Manager and Project Manager. She moved to Reliance in January 2003 to set up and lead clinical trial operations in the company. As Head, Advanced Development, she was responsible for establishing and maintaining monitoring, management, documentation and reporting standards and procedures, and ensuring adherence to all applicable regulations and guidelines for Phase IIIV clinical trial operations. She is currently charged with the responsibility of building a European clinical research focus for the company. Her responsibilities cover business development in Europe and USA and she has oversight for operations for trials conducted by the company in Europe. She is based in London. She has been a member of the DIA since 2000 and is a scientific reviewer for journals such as Contemporary Clinical Trials.
Dinesh V. Patel, PhD Dinesh Patel has over 23 years of experience in the pharmaceutical, biotech and biopharmaceutical industry. His current interest lies in incubating and/or growing companies focused on creating high value assets with low cost R & D operations (outsourcing) providing strategic, scientific, and operational guidance and/or leadership to life science companies working on ‘first/best in class’ type new chemical entities (NCEs). He is the founder and owner of IND AlChemist Inc, a private company specializing in drug discovery and IND through phase II POC based consulting and enabling services. He was most recently (2005-Jun’08) the President & CEO of Arete Therapeutics, a biopharmaceutical company focused on the discovery & development of small molecule ‘first in class’ anti-hypertensive and anti-diabetic agents. During 2003-05, he was the founder, President & COO of Miikana Therapeutics, an anti-cancer company that operated through synergistic integration of internal discovery and global outsourcing. Prior to Miikana, Dr. Patel was part of the founding management & scientific team that incubated Vicuron (1996-2003, originally named Versicor), and progressed over the years from positions of Director of medicinal chemistry to Senior VP of drug discovery and licensing. Prior to Vicuron, Dr. Patel was Director of drug discovery at Affymax (1993-96) and led their internal and collaborative efforts aimed at applications of combinatorial chemistry to drug discovery. Affymax provided the first outsourcing work to Syngene (subsidiary of Biocon, India) in 1994, and Dr. Patel actively managed and guided that activity. He began his career at Bristol-Myers Squibb in 1985 where he worked for eight years as a medical chemist and group leader encompassing different disease areas (cardiovascular, metabolic and oncology). Dr. Patel has more than 100 patents and publications to his credit, and has been actively involved in discovery and progression of numerous small molecule chemical entities through IND filing and phase II POC studies. He received his PhD in organic chemistry in 1984 from Rutgers, The State University of New Jersey and conducted post-doctoral research at the University of Wisconsin, Madison.